The invention relates to compositions and formulations comprising isolated acidic fraction of mastic gum and uses thereof for treating impaired neurological functions as well as wound and tissue repair.

The present invention provides recombinant adenoviral compositions and methods for their use in treating disorders associated with epithelial tissues.

Methods for de-differentiating or altering the life-span of desired recipient cells, e.g., human somatic cells, by the introduction of cytoplasm from a more primitive, less differentiated cell type, e.g., oocyte or blastomere are provided. These methods can be used to produce embryonic stem cells and to increase the efficiency of gene therapy by allowing for desired cells to be subjected to multiple genetic modifications without becoming senescent. Such cytoplasm may be fractionated and/or subjected to subtractive hybridization and the active materials (sufficient for de-differentiation) identified and produced by recombinant methods.

The present invention provides recombinant adenoviral compositions and methods for their use in treating disorders associated with epithelial tissues.

The present invention provides a method of forming a fibromodulin (FMOD) reprogrammed (FReP) cell.

This application includes the sequence listing which is identical to the sequence information in the last filed computer readable form (CFR) on Aug. 1, 2014 in U.S. application Ser. No. 14/353,284, filed Apr. 21, 2014, entitled 2014-08-01 384578-991391 ST25.tax and is hereby incorporated by reference in its entirety.

This invention generally relates to methods to obtain mammalian cells and tissues with patterns of gene expression similar to that of a developing mammalian embryo or fetus, and the use of such cells and tissues in the treatment of human disease and age-related conditions. More particularly, the invention relates to methods for identifying, expanding in culture, and formulating mammalian pluripotent stem cells and differentiated cells that differ from cells in the adult human in their pattern of gene expression, and therefore offer unique characteristics that provide novel therapeutic strategies in the treatment of degenerative disease.

In certain aspects the present invention provides engineered neural cells, neural stem cells, or neural progenitor cells that contain a nucleotide sequence that encodes an adenovirus E40RF1 polypeptide and/or that contain an adenovirus E40RF1 polypeptide. The present invention also provides methods of making and using such engineered cells and compositions comprising such engineered cells.

Methods for reprogramming cells by culturing the cells under a condition that allows formation of a three-dimensional cell aggregate are provided. The cells and cell aggregates obtained using the methods are also provided.

The present invention relates to a method for reprogramming a first cell type to an intermediate cell of a second cell type comprising the step of contacting the first cell with a first agent to modulate an integrin profile in the first cell type to provide an intermediate cell of the second cell type. The present invention also relates to a reprogrammed cell obtained by the method of the invention, a kit for reprogramming a first cell type to a second cell type as well as methods for treating a patient in need of cell based therapy, tissue replacement and cancer therapy.

The present disclosure relates to a construct or a vector for reprogramming stem cells, differentiated cells, or mixtures thereof into hemogenic and/or hematopoietic stem cell-like cells, wherein the construct or the vector encodes a peptide comprising a combination of two isolated or synthetic transcription factors, preferably at least three isolated or synthetic transcription factors. The disclosure also relates to a composition comprising said construct or vector, to a method for reprogramming or inducing a stem cell or a differentiated cell into hemogenic and/or hematopoietic stem cell-like cells comprising a step of transducing a cell with at least one of said vectors; to a induced hemogenic and/or hematopoietic stem cell-like cell obtained by said method; to a composition comprising said induced hemogenic and/or hematopoietic stem cell-like cell; and to a kit comprising at least one of the following components: the induced hemogenic and/or hematopoietic stem cell-like cell; the composition as described in any of the previous claims; the vector or the construct as disclosed; or mixtures thereof.